Review Article

Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications

Xiaotian Zhong and Jill F. Wright

Pfizer BioTherapeutics Research & Development, 87 Cambridge Park Drive, Cambridge, MA 02140, USA

Correspondence should be addressed to Xiaotian Zhong; xiaotian.zhong@pfizer.com

Received 14 February 2013; Accepted 20 March 2013

Academic Editor: Haruki Hasegawa

Copyright © 2013 X. Zhong and J. F. Wright. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Over the lifespan of therapeutic proteins, from the point of biosynthesis to the complete clearance from tested subjects, they undergo various biological modifications. Therapeutic influences and molecular mechanisms of these modifications have been well appreciated for some while remained less understood for many. This paper has classified these modifications into multiple categories, according to their processing locations and enzymatic involvement during the trafficking events. It also focuses on the underlying mechanisms and structural-functional relationship between modifications and therapeutic properties. In addition, recent advances in protein engineering, cell line engineering, and process engineering, by exploring these complex cellular processes, are discussed and summarized, for improving functional characteristics and attributes of protein-based biopharmaceutical products.

1. Introduction

Nature has evolved complex biological processes that enable mammalian cells to conduct sophisticated physiological activities for living and adaptation. Primary structure of a protein obtained from genome projects serves as a nice starting point for the understanding of biological complexity but not sufficient to explain various functions and regulations. Majority of proteins from eukaryotic cells are subjected to certain kind of covalent modifications either during or after their ribosomal synthesis. An increasing appreciation of these cellular homeostatic modifications, which have been shown to initiate various biological functions and regulation mechanisms, should contribute to unfolding detailed knowledge about biological networks and living systems.

One of the earliest pieces of evidences for the existence of posttranslational modifications can be traced back to the finding of protein phosphorylation published in 1883 [1, 2], in which protein casein was found containing stoichiometric amount of phosphate. One of the earliest modified proteins to be studied, the first glycoprotein, is likely the glycogen of liver which the French physiologist Claude Bernard famously identified as “glycogenous matter” in 1855 [3]. During the biosynthesis of all proteins, the building blocks are 19 standard amino acids (plus selenocysteine for a few selenoproteins) and one imino acid. Nonetheless upon hydrolysis, close to 200 different amino acids have been identified, indicating a significant posttranslational modification of the originally encoded sequences [4]. Over the years, more than 200,000 reported modification events have been unveiled by a PubMed analysis [5]. Several hundred modifications have been characterized to date [4, 6, 7]. Some of these modifications are spontaneous reactions, while most of them involve specific enzymes and pathways. Certain structural determinants within the primary sequences of polypeptides are recognized by cellular machineries, and are carefully regulated by time and space. Efficiency of these modifications varies according to cell types, availability of substrates and cofactors, and biological conditions.

Most therapeutic proteins approved or in development bear at least one or more of posttranslational modifications [8–10]. Majority of these proteins are originally synthesized in endoplasmic-reticulum-(ER-) bound ribosomes, translocated across ER membranes through translocon, and...
transported through the secretory pathway into extracellular space. A subset of modifications accompany along with this biological process, and additional modifications occur during in vitro manipulations, that is, purification, formulation, storage, and injection into test subjects. These modifications and their underlying molecular mechanisms form the main focus of this review. Other modifications that are characteristics of intracellular proteins, such as acetylation, ADP-ribosylation, sumoylation, and ubiquitination, can be found in several recent reviews [5–7, 11–14] and therefore not considered in this paper.

It is obvious that posttranslational modifications affect structural and functional aspects of therapeutic proteins. The effects can be detrimental, that is, heterogeneity [15] and immunogenicity [16], even though the modification may originally be required for functional activity of the polypeptide. A better understanding of the relationship between the primary sequences of therapeutic proteins and cellular machineries can allow developers to avoid unwanted side effects of these modifications. Such knowledge can also help improve protein efficacy and quality through protein engineering, cell line engineering, and process engineering. This review classifies these modifications into four major categories, three of which are based on the locations where these modifications take place within the trafficking events: ER, Golgi, and Exocellular space (Figure 1). N-linked glycosylation modification involves both ER and Golgi compartments, therefore being categorized as a separated group. In each of these categories, molecular mechanism and specific pathways for each modification are described (Table 1). The purpose of the review is restricted to modifications that may be found on therapeutic proteins secreted from animal cells. Therapeutic protein examples bearing the corresponding modification are discussed, and their effects on physiological and biophysical properties are analyzed. In the last part of the paper, recent progresses on protein engineering, cell line engineering, and process engineering, by utilizing posttranslational modification pathways, are considered and summarized (Table 2).

2. ER Modifications

During biogenesis in eukaryotic cells, precursor forms of therapeutic proteins are translated in ribosomes, which are targeted to rough ER through a hydrophobic signal sequence bound by a signal recognition particle ribonuclear protein complex [17]. Depending on the overall amino acid content of the protein, the translocation across ER membranes can occur co- or posttranslationally, both of which require protein translocon, the Sec61 complex [18]. In ER lumen, the protein has its signal peptide removed via membrane-bound signal peptidase, gains proper folding through ER luminal folding machinery, is subjected to ER quality control process, and transports to next secretory compartment. Several modifications take place for therapeutic proteins when they transit through this compartment. These modifications include disulfide bond formation, gamma carboxylation, beta hydroxylation, and N-linked glycosylation which is discussed in the latter section.

2.1. Disulfide Bond Formation. Disulfide bond formation is one of the most common modifications found in extracellular proteins. Therapeutic proteins, such as antibodies, coagulation factors, and insulin, contain both interchain and intrachain disulfide bonds. Disulfide bond formation helps stabilize tertiary structures and is important for assembly and maintenance of protein structural integrity. Without disulfide bonds, native conformations for these proteins are not obtained. For multi-unit proteins such as antibody, interchain disulfide bonds help connect multiple protein subunits together during polypeptide assembly.

Disulfide bond formation takes place in ER lumen where it is much more oxidizing than cytosol as measured by reduced-oxidized glutathione couple [19]. A highly specific and targeted redox protein network maintains this redox homeostasis and ensures proper disulfide bond formation [20, 21]. To attain a given conformation, native and nonnative disulfides are transiently formed and reduced. A precise equilibrium between oxidation and reduction reactions in ER is required to make certain that these covalent links remain dynamic until folding is completed. Either a reducing ER, preventing disulfide formation, or an overoxidizing ER, stabilizing nonnative bonds, can trigger ER stress responses [22].

Molecular pathways for disulfide bond formation have been discovered in eukaryotes and prokaryotes [21, 23]. Both systems share a common design, including the transfer of thiols between membrane-associated oxidoreductases to soluble oxidoreductases and direct introduction of disulfide bonds into substrate proteins. In mammalian cells, membrane-associated flavoprotein Ero1 utilizes the oxidizing power of molecular oxygen, coupled with its flavin cofactor, to generate disulfide bonds within itself, which are transferred to protein disulfide isomerase (PDI). Then PDI transfers its disulfide bonds directly to secretory proteins in ER. Both human and yeast cells contain multiple PDI-like proteins. These PDI homologs may contribute to discrete protein maturation pathways in different cell types [21]. Besides the Ero1-dependent pathway, alternative oxidative folding pathways, such as the quiescin sulphhydril oxidase/Erv superfamily and vitamin K epoxide reductase, also contribute to the cellular disulfide bond formation process [24].

Incomplete formation of disulfide bonds can cause issues like heterogeneity and disulfide bond scrambling for therapeutic proteins [15]. It has been reported that a significant fraction of free sulphhydryl and reactive cysteine residues is found in recombinant antibodies of IgG1, IgG2, and IgG4 [25]. Interchain disulfide bonds between heavy chains or between heavy chain and light chain are susceptible to reduction [26], while intrachain disulfide bonds within each IgG domain can only form free sulphhydril groups due to incomplete bond formation during biosynthesis. This formation of free sulphhydril group can increase molecular mass by 2 Da and result in size heterogeneity. Presence of incomplete disulfide bonding can induce disulfide bond scrambling and cause structural disturbances. Human IgG2 antibodies contain three types of disulfide isoforms classified by the disulfide links between Fab arms and heavy chain hinge region, contributing to IgG2 heterogeneity [27]. Human IgG4
2.2. Gamma Carboxylation of Glutamate Residues. γ-carboxylation is a type of modification with a conversion of target glutamate (Glu) residues to γ-carboxyglutamate (Gla), first discovered in 1974 in Prothrombin [29, 30]. This process is undertaken by a vitamin K dependent carboxylase (GGCX), an ER bound integral membrane protein with at least five transmembrane domains [31, 32]. In the presence of CO₂, O₂, and vitamin K hydroquinone, GGCX converts glutamate residues to Gla residues, yielding vitamin K epoxide and H₂O. The vitamin K epoxide is subsequently reduced to regenerate vitamin K hydroquinone by vitamin K epoxide reductase (VKOR) [33].

γ-carboxylation is a characteristic of a group of proteins termed vitamin K dependent proteins that play roles in blood coagulation and bone metabolism [34]. They contain this so-called Gla domain that possesses 9–12 Gla residues in a roughly 45 amino acids peptide sequence. Gla residues provide the calcium binding ability to the Gla-domain-containing proteins. This activity induces conformation changes for interacting with membrane phospholipids. Undercarboxylation of these proteins can severely impair their biological activities. Gla residue is not reused for protein synthesis but is excreted in urine for mammals [34]. Carboxylation of Gla domain is not dependent on a specific consensus sequence, but mediated by an immediately adjacent propeptide region. The propeptide contributes to docking protein substrate to GGCX and may also serve as an allosteric effector in trans [34].

Currently three therapeutic proteins are γ-carboxylated: factor IX, VIIa, and activated protein C. Another γ-carboxylated protein thrombin is used as a topical treatment for breeding control [35]. The recombinant factor IX contains 12 glutamic acids that can be carboxylated. High-level expression of factor IX in Chinese Hamster Ovary (CHO) cells decreases the carboxylation rate and therefore results in a much lower specific activity when compared to the natural human plasma-derived protein [36]. Factor X was found only 30% fully carboxylated when expressed in human embryonic kidney cells [37], likely due to the saturation of GGCX enzyme. Interestingly, replacing factor X propeptide with that of prothrombin, a 43-fold lower affinity substrate for GGCX, results in 90–95% of factor X being fully carboxylated. Factor VIIa contains 10 carboxylation sites that are important for its biological activities [38], and the recombinant version with 9 out of 10 sites carboxylated retains full activity. Activated protein C that is used to treat severe sepsis has 9 carboxylation sites, and full carboxylation of all sites is required for its biological activity [39].

2.3. Beta Hydroxylation of Aspartate and Asparagine. β-hydroxylation was first discovered in early 1980s from bovine protein C [40]. It is undertaken by hydroxylase enzymes that convert target aspartate (Asp) residues to β-hydroxyaspartate (Hya) or asparagine (Asn) residues to β-hydroxyasparagine (Hyn) [41–43]. This modification has also been shown to bind calcium and to be involved in protein–protein interaction. β-hydroxylation takes place in ER and requires 2-ketoglutarate and Fe²⁺ [41, 43]. This modification is catalyzed by a type II membrane protein β-hydroxylase with a C-terminal catalytic domain in ER lumen [42]. The reaction
Table 1: Consensus motifs and enzymes responsible for therapeutic modifications.

| Modification type | Linkage | Consensus sequence | Enzymes                  |
|-------------------|---------|-------------------|--------------------------|
| N-glycosylation   | GlcNAc-Asn | N-X-(S/T), X ≠ Pro | OST                      |
| Mucin-type        | GalNAc-Ser/Thr | No consensus, Pro favorable | ppGalNAcT               |
| Disulfide bond    | –S–     | Cysteine pairs    | Ero1-PDI                 |
| γ-carboxylation   | Glu → Gla | Mediated by adjacent propeptide | GGCX-VKOR     |
| β-hydroxylation   | Asn → Hyn; Asp → Hya | C-X-D/N-X-X-X-X-F/Y-X-C-X-C but not sufficient | β-hydroxylase |
| Tyrosine sulfation| O4-sulfate ester | No simple consensus site | TPST1/TPST2            |
| Propeptide cleavage| R/K ↓ | With single or pair of basic amino acids | PC family members |
| Phosphorylation   | pS, pT  | S-x-E/pS or Ser/Thr | FAM20C or four-jointed PAM |
| Amidation         | C-terminal carboxyl → amide | C-terminal glycine | PAM                      |
| Deamidation       | Asn → Asp; Gln → Glu | Asn-Gly most susceptible | Unknown or none |
| Glycation         | Ketoamine or Amadori product | N-terminal primary amine | Unknown or none |
| Pyroglutamate     | Pyrrolidone carboxylic acid | N-terminal Gln or Glu | Unknown or none |
| Oxidation         | Met → Met sulfoxide | Met (Trp, Cys, Tyr, His) | Unknown or none |
| Proteolytic processing | Arg ↓ or ↓ Lys | Basic amino acid | APC, carboxypeptidase B |

does not require vitamin K or an adjacent propeptide. A consensus β-hydroxylation site (Cys-X-Asp/Asn-X-X-X-X-X-Phe/Tyr-X-Cys-X-Cys) found in EGF domain was proposed [44]; however, proteins like factor VII with such a site is not hydroxylated, suggesting that further requirements are needed [38].

β-hydroxylation is found in epidermal growth factor (EGF) precursor and in some calcium-binding EGF-like domain receptors, ligands, extracellular matrix proteins, complement proteins, and vitamin K dependent homeostatic proteins [35]. It occurs in therapeutic protein factor IX and protein C. Both plasma-derived factor IX and recombinant factor IX from CHO cells are similarly hydroxylated at Asp64 (∼30–40%) [45]. Hydroxylation seems to be nonessential for the clotting activity. On the other hand, hydroxylation of activated protein C at Asp71 is essential in maintaining its biological activity in factor Va and factor VIIIa inactivation [10, 39].

3. Golgi Modifications

Golgi complex is well established as a central processing and sorting station for protein trafficking [79] and as an organelle with multiple complex functions [80]. In mammalian cells, Golgi stacks are laterally linked to form a ribbon-like membrane system. When neosynthesized and properly folded soluble therapeutic proteins exit ER, membrane vesicles containing these proteins fuse with a network of vesicular tubular clusters known as ER-Golgi intermediate compartment that sorts proteins to cis-Golgi or carries them back to ER. While the Golgi-arrived proteins transverse Golgi cisternae and sort further at trans-Golgi network to various cellular destinations, they are subjected to a number of modifications.

3.1. Tyrosine Sulfation. Sulfation addition to tyrosine of secretory proteins as an O4-sulfate ester takes place in trans-Golgi [81]. This modification was first discovered in 1954 in a bovine fibrinogen peptide [82]. Since then hundreds of tyrosine-sulfated proteins have been reported [83–86]. The modification is mediated by two closely related integral membrane protein tyrosylprotein sulfotransferases (TPST1 and TPST2) [87–89], with the catalytic domain oriented in the lumen of trans-Golgi [90, 91]. Orthologues of TPST1 and TPST2 have been found in both vertebrate and invertebrate [84], supporting functional importance of this modification, although no tyrosine sulfation occurs in yeast or prokaryotes.

The reaction catalyzed by TPSTs employs 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as sulfate donor [83], in which the sulfate from 5'-phosphosulfate group of PAPS is transferred to the phenol of a tyrosine residue to form an O-sulfated tyrosine and adenosine 3',5'-diphosphate [84]. There is no simple consensus sequence for tyrosine sulfation, although certain common features have been identified based on the sequence analysis with known sulfated tyrosines that seem to favor this modification. One of the major characteristics is the presence of acidic amino acids, such as aspartic or glutamic acid, adjacent to tyrosine at N-terminal end [81, 87, 92]. Turn-induced amino acids around tyrosine residue, as well as lack of cysteine and glycosylation sites, favor sulfation of nearby tyrosine residues [81, 92].

For therapeutic proteins, tyrosine sulfation is required for factor VIII’s full procoagulant activity, including conversion of factor VIII to VIIIa and optimal binding to von Willebrand factor [36]. Tyrosine sulfation at 155 in factor IX influences factor IX’s in vivo recovery [36]. The functional importance of tyrosine sulfation appears to be modulating biological activity and binding affinities by affecting protein-protein
### Table 2: Biopharmaceutical applications of therapeutic protein modifications.

| Applications                        | Function/gene               | Mechanism of action                      | Reference |
|-------------------------------------|-----------------------------|------------------------------------------|-----------|
| (1) Protein engineering             |                             |                                          |           |
| Disulfide bond introduction         | Cysteine engineering        | Stabilizing FVIIa                        | [46]      |
| N-linked site introduction          | Half-life extension of EPO  | Reducing renal clearance                 | [48]      |
| Poly O-linked sites                 | IgG framework/CDR           | Improving solubility                     | [49, 50]  |
| Engineering N-terminal Gln         | Fusion of CTP of gonadotropin | half-life extension                      | [51, 52]  |
| Protease resistant mutant           | Mutating Arg336 & 562 of FVIII | Preventing N-terminal degradation        | [53]      |

(2) Cell-line engineering

| Applications                        | Function/gene               | Mechanism of action                      | Reference |
|-------------------------------------|-----------------------------|------------------------------------------|-----------|
| Overexpressing GnTI, GnTV,         | Increasing sialic acid content | See text                                |           |
| ST3GalIV, and ST6GalI              |                             |                                          |           |
| CMP-sialic acid transporter         |                             |                                          |           |
| CMP-sialic acid synthase, GNE       |                             |                                          |           |
| Knockdown sialidase                 | Preventing sialic acid degradation | [59, 60]   |
| CMP-sialic acid hydroxylase         | Preventing conversion of Neu5Ac to Neu5Gc | [61]       |
| Knockdown ST3Gal                    | Enhancing sLeα formation    | [62, 63]                                 |
| Overexpressing C2GnT, Fut6          | Fucose removal              | [64, 65]                                 |
| Knockout or knockdown               |                             |                                          |           |
| FuT8, GMD, overexpressing GnTIII    |                              |                                          |           |
| Inactivating GnTI                   | Oligomannose formation      | [68, 69]                                 |
| Improving ADCC                      | Overexpressing sialidase    | Reducing sialylation                     | [70]      |
| Improving carboxylation             | Overexpressing VKOR         | Facilitating vitamin K reduction         | [71]      |
| VKOR ↑ calumenin ↓                  | Increasing carboxylation of FVII | [72]         |

(3) Process engineering

| Applications                        | Function/gene               | Mechanism of action                      | Reference |
|-------------------------------------|-----------------------------|------------------------------------------|-----------|
| Modulating glycosylation            | Serum content, pH, dissolved oxygen, Temperatures, ammonium, salt concentration | Bioprocessing parameters | See text |
| Glucosamine/uridine                 | Enhancing glycan antennarity | Elevating intracellular UDP-GlcNAc       | [73]      |
| Lipid supplement                    | Maintaining site occupancy  |                                          | [74]      |
| Decreasing temperature/adding butyrate | Enhancing glycan occupancy | Increasing site exposure to OST          | [75]      |
| Addition of ManNAc                  | Improving sialylation       | CMP-Neu5Ac precursor                     | [76]      |
| Adding manganese/iron               | Enhancing glycan occupancy  | Increasing OST activity                   | [75]      |
| Addition of kifunensine             | Oligomannose formation      | α-mannosidase I inhibitor                 | [77]      |
| Lowering glucose                    | Reducing heterogeneity      | Reducing glycation                        | [78]      |

3.2. Propeptide Processing. Many bioactive proteins and peptides are synthesized as an inactive precursor which is activated by limited proteolysis. The specific processing of these proproteins and prohormone peptides occurs at relatively conserved sites often with single or pairs of basic amino acids [97, 98]. A special family of proteases, termed preprotein convertases (PCs), process these inactive precursors while they traffic through the secretory pathway. Seven members of this PC family are basic amino acid specific mammalian proteases that are known as PC1/3, PC2, Furin, PC4, PC5/6, PACE4, and PC9 [98]. Many chemokine receptors, G-protein-coupled receptors of complement proteins, phospholipids, and glycoprotein hormone receptors, have been shown to be tyrosine sulfated, which play an important role in their high affinity ligand binding and subsequent receptor activation. C-terminal tyrosine sulfated hirudin displays tenfold higher affinity to thrombin than the unsulfated version [93–95]. Tyrosine sulfation also appears to affect protein stability, as human secreted fizzled-related protein-1 is less stable with the presence of sulfation in its tyrosines 34 and 36 [96].
and PC7 [98]. The eighth member of the family is SKI-1 that cleaves substrates at the motif (R/K)-X-(hydrophobic)-X [99]. The latest member of the family is PCSK9 that autocatalytically cleaves its propeptide at VFAQ152 [100].

All these convertases themselves are synthesized as inactivezymogens. Through an autocleavage event in ER or in immature secretory granules (for PC2 only), an inactive heterodimer of inhibitory propeptide associated with the rest of the protein is formed. After exiting ER, a second autocatalytical event occurs on the prosegment at specific subcellular compartments along the secretory pathway to liberate the active enzyme free from the inhibitory propeptide [98]. This activation mechanism ensures that these PCs are only active at specific intracellular sites. SKI-1, Furin, PACE4, PC5/6, and PC7 are active at the Golgi complex, PCI/3 and PC2 are maximally active in secretory granules, while PCSK9 is the only PC that is secreted as catalytically inactive heterodimer [98].

A number of therapeutic proteins or peptides are synthesized as proproteins. Proinsulin is processed by either PCI or PC2 [97]. Bone morphogenetic protein-2 precursor [101] is specifically processed by PC5/6 [102]. The presegments of both Pro-factor VII [97] and Pro-factor IX [103] are processed by Furin. Failure to remove the propeptide from Pro-factor IX can result in a secretable molecule that is defective in phospholipid interaction and displays reduced γ-carboxylation of glutamic acid residues [104]. Factor VIII is processed at arginine 1313 and 1648 of its B-domain which has consensus site for Furin, though the exact PC members responsible for this processing remain unidentified [105].

3.3. O-Linked Glycosylation. In contrast to N-linked glycosylation which initiates cotranslationally in ER lumen with a transfer of a core glycan chain from dolichol-pyrophosphate, O-linked glycosylation in mammalian cells begins in Golgi apparatus with addition of single monosaccharide from sugar nucleotide precursor [106, 107]. Several types of O-linked glycosylation can be classified. Mucin-type glycans have N-acetylgalactosamine (GalNAc) attached to hydroxyl group of Ser or Thr, which are found on many secreted and membrane-bound glycoproteins. No particular sequence motif has been identified for mucin-type O-linked glycosylation, except with proline favorable and charged amino acids interfering nearby specific sites [106, 107]. Elongation of this GalNAc generates at least eight different core structures. Some other specific types of O-linked glycosylation have also been identified. O-linked fucoses and glucose are found on a specific consensus sequence in EGF protein domains [108]. One special O-linked glycosylation is galactose (Gal) on hydroxylysines of collagen in the sequence of Gly-Xaa-Hyl-Gly- [109]. Another special kind of O-linked glycans is glycosaminoglycans (GAGs) that are typically found in proteoglycans produced virtually by all mammalian cells [110]. GAGs are linked to serine residues in core protein by xylose. Xylosyltransferase initiates this modification in Golgi at specific sites defined by Ser-Gly flanked with one or two acidic residues. Mucin-type of O-linked glycosylation can be often found in therapeutic proteins. The first step for this modification is the transfer of GalNAc to Ser or Thr, catalyzed by a polypeptide-N-acetyl-galactosaminyltransferase (ppGalNAcT). There are at least 21 ppGalNAcT homologs expressed in eukaryotic organisms [111]. ppGalNAcT expression and its Golgi sublocalization vary considerably between cell types and tissues, contributing partly to heterogeneity of O-linked glycans. Further elongation and termination of O-linked glycans after addition of the first GalNAc can be synthesized by various glycosyltransferases. Expansion with galactose, GlcNAc, or GalNAc produces eight different core structures. The glycans can be additionally modified by sialylation, fucosylation, sulphatation, methylation, or acetylation, which lead to a large number of oligosaccharide structures [107, 111].

Like N-glycans, O-linked glycans play a role in maintaining structures of fully folded proteins, modulating aggregation, maintaining protein stability, and conferring protease and heat resistance. O-linked glycan modifications have been found in hinge region and possibly Cc region for a number of antibodies [15]. The hinge region modification can render protease resistant for antibody. Examples include modifications at the hinge regions of IgG2b [112], IgA1, and IgD [107, 113]. O-linked modification in human erythropoietin (EPO) is not essential for its activity [114]. O-linked glycans are also found in the activation peptides of factor V and VIII and in the EGF domain of factor IX, VII [36], tissue plasminogen activator [115], and recombinant human urokinase [116]. The functional significance of these glycans remains unclear. One of the adverse effects of O-linked glycans on therapeutic proteins is heterogeneity [15, 107]. Recently O-linked glycans are found inhibiting the binding activity and efficacy of a therapeutic peptide-antibody bispecific fusion by blocking its interaction with cytokine IL7A [53].

3.4. Phosphorylation. Intracellular protein phosphorylation has been well documented as a fundamental mechanism regulating many essential cellular processes; yet physiological importance and functional regulation of extracellular phosphorylation on extracellular proteins remain obscure comparatively. Recent proteomic and computational analysis has revealed a large number of extracellular phosphorylated proteins and phosphorylated sites [117]. It also provides evidence that extracellular phosphorylation plays a role in various physiological functions, such as blood coagulation, formation of neuronal networks, immune cell activation, and biomineralization [2, 117, 118].

It has been long assumed that the concentration of ATP is not sufficiently high in extracellular environment, even though constitutive release of ATP extracellularly has been observed in many cell types [119–121]. The most recent proof for extracellular phosphorylation events is the identification of two Golgi-localized ectokinases, four-jointed [122], and FAM20C [2, 118]. Both proteins contain an N-terminal signal sequence and a kinase domain. FAM20C has been demonstrated to be the long-sought "Golgi-enriched fraction casein kinase" (GEF-CK) that phosphorylates many extracellular proteins. The consensus site recognized by GEF-CK is S-x-E/pS, where X can be any amino acid and E/pS can be Ghu or phosphoserine [2, 118]. Another FAM20 member, FAM20B,
has been identified as an ectokinase that phosphorylates xylose within GAG core linker [124]. These findings are consistent with the notion that extracellular phosphorylation mainly takes place in the Golgi compartment, where sufficiently high concentration of luminal ATP provides phosphorylation substrates and is the source of constitutively released ATP into the extracellular space of many cell types [121].

A number of therapeutic products or candidates have been found phosphorylated. Two well-known examples are coagulation factors. Plasma-derived factor IX is fully phosphorylated at serine 158, but recombinant factor IX is not phosphorylated [125], suggesting that ectokinases in CHO cells may be insufficiently expressed. Although the absence of phosphorylation modification does not affect in vitro clotting activity, the effect on the in vivo clotting activity remains unknown. Factor VIII is also found phosphorylated when exposed to activated platelets [126]. Similar data was also obtained for factor V. Phosphorylation of these two cofactors seems to downregulate their activities, since partially phosphorylated factor Va appears to be more sensitive to activated protein C inactivation [36]. Biologically active peptide hormones, such as adrenocorticotropic [127] and progastrin [128], are found phosphorylated. It would be of interest to know if FAM20C or four-jointed is the right ectokinase responsible for phosphorylating these proteins in vivo.

3.5. Amidation. Amidation is a replacement of C-terminal carboxyl group of a protein with an amide group. This is a typical modification of many bioactive peptides for full activity [129, 130]. Amidation is ubiquitously found in higher eukaryotes but not in yeast or prokaryotes. Peptide hormones are produced as glycine-extended intermediates, and then the glycine N–C alpha bond is oxidatively cleaved to form active amidated hormones.

Amidation reaction is catalyzed by two enzymes: peptidylglycine α-hydroxylating monooxygenase (PHM) and peptidyl-α-hydroxylglycine α-amidating lyase (PAL). In mammals and higher organisms, these enzymes are expressed as a single bifunctional enzyme, peptidylglycine alpha-amidating monooxygenase (PAM) [130]. The PHM catalyzes the reduction of molecular oxygen for the hydroxylation of the glyine α-carbon of glycine-extended substrates, with two redox-active copperes reduced by ascorbate. The PAL produces α-amidated peptide product and glyoxalate by cleaving the glycine N–C alpha bond from the peptidyl α-hydroxyglycine intermediate. The PAM enzyme localizes in the distal trans-Golgi network through its cytosolic domain [131].

The exact biological roles of α-amidation remain to be fully elucidated. This modification prevents ionization of the C-terminus of peptides. It may therefore render it more hydrophobic and better bind to its receptor [130]. It may also contribute to peptide stability. Recombinant salmon calcitonin that regulates serum calcium and phosphate levels is amidated [132]. The product (Forcaltonin) is for the treatment of Paget’s disease and hypercalcaemia. It is produced in E. coli as a fusion protein and needs downstream in vitro modification with a recombinant α-amidating enzyme. It is known that CHO, COS-7, and NIH-3T3 can allow amidation of secretory products with an engineered C-terminal glycine [133, 134]. Therefore recombinant bioactive peptides and their fusion proteins could presumably be produced with an in vivo approach.

4. N-Linked Glycosylation

N-linked glycosylation is the most common posttranslational modification found in eukaryotic cells, contributing to many crucial biological and physiological roles [III, 135]. The sophisticated modification process involves both compartments of ER and Golgi. The consensus site for N-linked glycosylation is the sequon of Asn-X-Ser/Thr where X can be any amino acid except proline [136, 137]. Acidic amino acids such as aspartate and glutamate can also reduce efficiency. Glycosylation at Asn-Ala-Cys has also been reported [138]. Glycosylation efficiency of these Thr, Ser, and Cys containing sequon is very different with an order of Thr>Ser>Cys [139]. Some nonstandard sequons have been recently identified for N-linked oligosaccharide modification in a small percentage of human recombinant antibodies [140].

N-linked oligosaccharides are added to proteins en bloc in the lumen of ER as presynthesized core units of 14 saccharides (Glc3Man9GlcNAc2) in virtually all eukaryotes [137, 141]. This core glycan is the product of a biosynthesis pathway in which monosaccharides are added to a lipid carrier (dolichol pyrophosphate) on both sides of ER membranes by monosaccharyltransferases in the membranes. These enzymes are called ALG (for Altered in glycosylation), identified from studies of yeast mutants. The sugar moiety is translocated from cytosolic side to the luminal side of ER by an ATP-independent bidirectional flipase [142]. The oligosaccharyltransferase (OST) then scans the emerging polypeptide from translocon complex for glycosylation sequon and adds the core glycan unit to the side chain nitrogen of the Asn residue by N-glycosidic bond [141, 143]. Three oligosaccharyltransferase complexes have been identified in mammals; each contains one of two Stt3 proteins, the presumed catalytic units. After the core glycan is added to the growing nascent polypeptide chain, the oligosaccharide portin is modified by a series of glycosidases. Glucosidase I and II, located in the ER, remove all three glucose residues from the core unit to produce a Man9GlcNAc2 high mannose structure.

This ER modification process choreographs with protein folding cycle of many glycoproteins, in which glycans serve as sorting signals reflecting the folding status of the protein. The monoglycosylated glycans after the action of glucosidase I and II are bound to two ER lectin chaperones, calnexin or calreticulin, which prevents protein aggregation and ER exit of partially folded proteins [136]. This binding exposes the glycoprotein to the binding of ERP57, the protein disulfide-isomerase A3, for protecting from nonproductive disulfide bonding. When glucosidase II removes the remaining glucose residue, the glycoprotein no longer binds to the lectins and is free to exit ER unless recognized by UDP-Glc:glycoprotein glucosyltransferase (GT). GT can reglucosylate incompletely
folded glycoproteins and reinitiate the lectin chaperone binding. The repeated cycles of GT and glucosidase II facilitate efficient folding of newly synthesized glycoprotein. The unsalvageable misfolded proteins are subject to the ER-associated degradation process [136]. For correctly folded-glycoproteins, many of them are further acted by ER α-mannosidase I, before exiting ER, to have terminal mannose removed from the central arm of ManαGlcNAc2.

In the cis-Golgi, α-1,2 mannosidase IA, IB, IC further trim 4–6 terminal mannose to produce a ManαGlcNAc2, a key intermediate for hybrid and complex N-glycans [141]. An N-acetylgalactosaminyltransferase named GnTI in medial-Golgi adds a GlcNAc residue to C-2 of the mannose al-3 in the core of ManαGlcNAc2. After this step, majority of N-glycans are trimmed by α-mannosidase II to form GlcNAcManαGlcNAc2. Then a second GlcNAc is added by the action of GnTIII to yield the precursor for all biantennary complex N-glycans. Those glycans not digested by α-mannosidase II become precursors of hybrid N-glycans. A “bisecting” GlcNAc can be added to the core β-mannose by GnTIII enzyme for both complex and hybrid N-glycans. Further sugar additions and maturation, most of which occur in the trans-Golgi, add fucose, galactoses, GlcNAc, sialic acids, and sulfate to convert limited glycan repertoire into an extensive array of mature complex oligosaccharides [111].

N-glycans are most commonly found in therapeutic proteins [9, 10]. The presence and nature of the oligosaccharides clearly affect these proteins’ folding, stability, trafficking, immunogenicity, and their primary activities. It is well known that the N-glycans at Asn297 in Fc region of recombinant antibodies and Fc fusion proteins are critical to the activation of downstream effector mechanisms. The Fc oligosaccharides are different from those typical N-glycans and are predominantly fucosylated nongalactosylated diantennary oligosaccharides, with a small portion of galactosylated sialylated diantennary oligosaccharides. The difference may be due to the inaccessibility of Fc N-glycan for further modification, as the N-glycans at the Fc regions are integral to the IgG structure and have a defined conformation [144]. Besides Fc core glycans, about 30% of polyclonal human IgG molecules contain N-linked oligosaccharides within the IgG-Fab region [144]. Therapeutic antibody cetuximab has an N-linked glycan at Asn88 of the heavy chain variable region and an unoccupied N-linked motif at Asn41 of the light chain variable region [145]. Fab oligosaccharides are more a normal type of N-glycans with heterogeneous complex diantennary and hybrid oligosaccharides with sialic acids and galactoses.

N-glycans also affect many nonimmunoglobuloproteins such as growth factors, cytokines, hormones, and therapeutic enzymes. Removal of either two or all three N-linked sites of human EPO results in poor product secretion [146]. Inhibiting glycosylation decreases biological activity and circulatory half-life of interferon (IFN)-β and IFN-γ, even though glycosylation is not essential for IFNs protein efficacy or safety [147]. Oligosaccharide structures of follicle-stimulating hormone heterodimer play an important role in its biosynthesis, secretion, metabolic fate, and functional potency [148]. The glycans at each subunit seem to exhibit distinct roles, with those in α subunit being critical for dimer assembly, signal transduction, and secretion, and those in β subunit being more crucial for circulation clearance. In addition, many therapeutics enzymes such as recombinant human glucocerebrosidase for Gaucher disease [68] are glycoproteins and N-glycosylation is important for targeting and functional activities. Factors V, VIII, IX, and X contain N-linked glycosylation [36]. Removing N-glycans from recombinant factor IX drastically increases its specific activity. N-linked glycosylation is essential for the secretion of both factors V and VIII.

5. Exocellular Modifications

Soon after therapeutic proteins complete the trafficking pathways and reach cell surface, they are released into extracellular medium environment and incubated there during the production period. Then they are purified, formulated, and stored. They can go into test subjects almost exclusively through parenteral routes such as intravenous, subcutaneous, or intramuscular injection [149]. Systemic circulation allows these proteins to be limitedly distributed into various tissues. Therapeutic proteins are then metabolized and eventually cleared out of the test subjects. A number of modifications occur to proteins when they are in the extracellular media, during in vitro manipulation, and in vivo circulation.

5.1. Deamidation. Nonenzymatic deamidation of asparagine and glutamine residues to aspartate and glutamate is a common modification for proteins [150, 151]. It is a hydrolytic reaction with water to form products through the formation of succinimide intermediate [151, 152]. Deamidation of Gln is slower than that of Asn. The deamidation rate is affected by conditions of pH, temperature, and ionic strength [151]. The rate also depends on the sequence around Asn and Gln. Polar residues preceding Asn and Gln, neighboring with Ser and Thr, can increase deamidation rates. Asn followed by Gly is found to be the most susceptible site [152]. Secondary, tertiary, and quaternary structures also influence deamidation reaction.

Deamidation of Asn and Gln contributes to charge heterogeneity of therapeutic proteins, since more acidic species are introduced by adding one negative charge and by decreasing isoelectric point [15, 151]. It has been shown that deamidation of Asn and Gln determines the irreversible thermal denaturation of proteins at acidic and neutral pH. Deamidation also affects protein crystallizability and X-ray diffraction due to microheterogeneity. Deamidation regulates the rate of protein breakdown, and could shorten in vivo half-life [151]. Both human insulin and growth hormone have been found to deamidate slowly in different formulations, affecting biological potency [151]. Deamidation commonly occurs for recombinant monoclonal antibodies under various conditions and at various domain regions such as CDRs, CH1-3, and CL [15], contributing to heterogeneity and instability, and presumable efficacy.

5.2. Glycation. Glycation is a nonenzymatic condensation reaction between a carbonyl group on reducing sugars and
N-terminal primary amine or the amine group of lysine side chains [153]. Glycation can occur to physiological proteins in human body where it is implicated in the pathogenesis of multiple chronic diseases [154, 155].

It has been shown that glycation can happen to recombinant antibodies during cell culture [156, 157], which generates product heterogeneity and may affect product stability [158]. Glycation to various antibodies can also take place in vitro, such as storage with lactose [159]. Glycation can disguise positive charges of N-terminal primary amino group or side chains of lysine residues, making the antibody more acidic [15]. It can reduce immunoreactivity of antibodies [160]. It has been reported that lowering the concentration of glucose in the fedbatch culture can control the glycation level of a recombinant antibody in CHO cells [78].

5.3. N-Terminal Pyroglutamate Formation. It has been well known that N-terminal Gln residue can readily cyclize with its own terminal amino group to form pyrrolidone carboxylic acid [161]. It remains uncertain whether or not the conversion reaction is nonenzymatic [162, 163]. Pyroglutamate is frequently detected in heavy chain and light chain of antibodies. N-terminal residues of human IgG heavy chains typically start with either glutamine or glutamate [164], while Lambda light chains begin with glutamine occasionally with serine, arginine, or leucine [165] and Kappa light chains with glutamate or aspartate [166–168]. The N-terminal glutamate can also be cyclized to form pyroglutamate.

The formation of N-terminal pyroglutamate from Gln and Glu decreases molecular mass by 17 and 18 Da. It also causes a loss of positive charge at neutral pH from a loss of the N-terminal primary amine, making the antibody more acid [15]. Antibody with pyroglutamate elutes earlier than those with glutamine on cation exchange column. Pyroglutamate formation is found resistant to amino peptidases and therefore is proposed as a stabilization mechanism [169]. It has been recently demonstrated that engineering an N-terminal pyroglutamate to a peptide-antibody bispecific genetic fusion molecule can restore its IL17A neutralizing activity in a cell-based assay by preventing N-terminal degradation [53].

5.4. Oxidation. Methionine, one of the most susceptible residues for oxidation, can be oxidized to methionine sulfoxide for therapeutic proteins such as antibodies [15] and growth factors [170]. This increases the mass by 16 Da and makes the side chain of Met more polar. Met255 and Met431 in the Fc region of human IgG are two most susceptible sites for oxidation when incubated at elevated temperatures [171]. These two residues are close to the CH2-CH3 interface [172], making them more susceptible. Antibodies with oxidized Met elute earlier relative to nonoxidized molecule on HIC column [171].

In addition to Met residues, Trp and Cys amino acids are also susceptible to oxidation. Oxidized Trp residues have been reported to be located in the CDRs regions for several antibodies [173–175]. Cys residues of antibodies are typically involved in disulfide bonding, but oxidation of unpaired Cys of a murine antibody is reported after a long storage [176]. Oxidation of histidine and tyrosine is also reported [177].

5.5. Proteolytic Processing. Proteolytic processing is a common modification in the extracellular space. Besides the nonspecific protein degradation mediated by various plasma and tissue proteases, some proteolytic processes are explicitly required for enzyme activation. Native protein of recombinant activated protein C, Xigris, is produced and circulated as a zymogen which is activated by thrombin in complex with thrombomodulin [178]. In plasma, factor VIII is activated by thrombin by the cleavage initially after Arg740 and then after Arg372 and Arg1689 to produce a heterotrimer [36]. It can be inactivated by activated protein C at Arg336 and Arg562. Factor V is activated by Thrombin at Arg739, Arg1018, and Arg1545, and inactivated by activated protein C at Arg306 and Arg506 [36]. Factor IX is activated by factor Xla to remove activation peptide. Factor X is activated by the cleavage of the tissue factor/factor VIIa complex or the factor VIIa and factor Xa complex.

C-terminal lysine removal of antibody heavy chain is a common modification of recombinant antibodies. It decreases the molecular mass by 128 Da and 1 unit of positive charge. Mammalian cell lines such as CHO, NSO, and SP2/0, produce an endogenous carboxypeptidase B that can result in this processing [179]. Partial removal of this residue can cause heterogeneity.

6. Biopharmaceutical Applications of Protein Modifications

Posttranslational modifications have been utilized as strategies for therapeutic improvements [9, 10, 144]. A better understanding of structure and function relationship as well as molecular pathways has facilitated the development of next generation of biotherapeutic products. The following summarizes the recent advances in protein engineering, cell line engineering, and process engineering, for improving functional characteristics and attributes of biopharmaceutical products (Table 2).

6.1. Applications in Protein Engineering. Engineering disulfide bonds by introducing cysteines into proteins have long been a protein engineering strategy for stabilizing small proteins and multiunit proteins [180–183]. In order to prolong the activity of factor VIIIa, Tyr664 and Thr1826 are mutated to Cys to introduce a disulfide bond between A2 and A3 domains [46]. The resulting protein significantly prolongs factor VIIIa stability and activity. A similar result is obtained for factor Va when a disulfide bond between its A2 and A3 domain is introduced [184]. Disulfide bond has also been introduced to framework region of antibody Fv fragments to improve stability [47]. It improves stability of IgG-like scFv antibody [185]. Also an in vivo cleavable disulfide linker has been designed for in vivo release of granulocyte colony-stimulating factor from its transferrin fusion [186].
Interchain disulfide bonds of IgG\textsubscript{1} can be distinguished by chemical reduction and oxidation method [187]. Cytotoxic drugs are therefore conjugated to antibodies through these activated cysteine sulfhydryl groups [188]. To resolve the issue of heterogeneity and to improve therapeutic index (defined as the lethal dose of a drug for 50% of the population divided by the minimum effective dose for 50% of the population), cysteine substitutions at positions of light chain and heavy chain have been applied successfully for site-specific conjugation [189, 190].

One of the best known examples making use of protein modification, the so-called glycoengineering, is the half-life extension of Aranesp [48, 191]. After introducing 48 N-linked positions and evaluating 62 constructs, the terminal half-life of Aranesp with two additional N-glycans is approximately 3-fold longer than that of wild-type Epoetin Alfa when administered intravenously. This is due to the fact that glycosylation can shield nonspecific proteolytic degradation, reduce renal clearance by negatively charged sialic acids at glycan chain termini, and decrease kidney glomerular filtration by increased molecular weight and hydrodynamic radius of the glycoprotein.

Glycoengineering has also been applied to improve the solubility and physicochemical properties of therapeutic proteins such as antibodies. Introducing N-linked glycans into antibody framework regions can increase protein solubility by more than 50-fold [49]. Similar results are obtained when an N-linked site is introduced to the CDR region [50].

O-linked glycan has also been applied to protein engineering. The carboxyl-terminal peptide (CTP) of human chorionic gonadotropin-\(\beta\)-subunit [52] contains several proline and serine residues and four O-linked oligosaccharides sites. When this CTP sequence is fused to human follitropin [192], erythropoietin [51], or human growth hormone [193], it increases the half-life of the fusion proteins in the circulation. This is also presumably due to the negatively charged sialic acids on the O-linked glycans that decrease renal clearance and glomerular filtration.

Modifying proteolytic processing is another strategy for improving therapeutic efficacy. Engineering an N-terminal glutamine to form pyroglutamate has been successfully applied to restore cellular activity of a peptide-antibody fusion by preventing N-terminal protein degradation [53]. Modifying proteolytic specificity of activated protein C toward serine protease inhibitor family proteins has helped improve their pharmacokinetic profiles [194]. Pipe and Kaufman generated an protease resistant FVIIIa by eliminating two APC cleavage sites at Arg336 and Arg562 [54].

6.2. Applications in Cell Line Engineering. Genetic engineering of host cell lines has proven to be a practical tool to obtain therapeutic proteins with improved properties. Due to the importance and prevalence of glycosylation on therapeutic proteins, a significant progress in cell line engineering by utilizing glycosylation pathways has been made for the past two decades [9, 10, 144, 195, 196].

Terminal capping of glycans with sialic acids improves \textit{in vivo} circulation half-life of glycoproteins because of negative charge and unrecognized asialoglycoproteins and mannose receptors. A number of cell line engineering efforts have been put in place. Overexpressing GnTIV and GnTV have been found to increase glycan proportion with tri-antennary and tetra-antennary structures [197, 198]. Further overexpressing ST3 \(\beta\)-galactoside \(\alpha\)-2,6-sialyltransferase IV (ST3GalIV) and/or ST6 \(\beta\)-galactoside \(\alpha\)-2,6-sialyltransferase I (ST6GalI) increases sialylation up to 80%. ST6GalI, which transfers sialic acid in an \(\alpha\)-2,6-linkage, is not expressed in CHO. Overexpressing this gene increases the \(\alpha\)-2,6-linked sialic acid over \(\alpha\)-2,3-linked sialic acid, which is reported to improve circulation half-life [199, 200]. Overexpression of both \(\beta\)-1,4-galactosyltransferase and ST3Gal also improves sialylation [58, 201].

Sialidase can degrade sialic acid when released into the culture due to cell lysis [202, 203]. Sialidase knockdown with stable antisense or siRNA in CHO is found to increase sialic acid content of recombinant glycoproteins [59, 60]. Overexpressing CMP-sialic acid transporter is shown to improve IFN-\(\gamma\) sialylation [56]. Overexpressing a key enzyme GNE for sialic acid synthesis can also improve sialylation of recombinant EPO [57]. A combinatorial approach with ST3Gal, CMP-sialic acid synthase, and CMP-sialic acid transporter, is found to better improve sialylation than overexpressing individual gene alone [55, 58].

On the other end, to generate antibody with reduced sialylation, the catalytic domain of the arthrobacter ureafaciens sialidase is stably expressed in mammalian cells [70]. The soluble sialidase A is secreted into medium where it is capable of removing sialic acid thoroughly from antibodies. The low sialylated antibody possesses improved antibody-dependent cellular cytotoxicity (ADCC) activity.

N-acetyleneuraminic acid (Neu5Ac) can be converted into N-glycolyneuraminic acid (NeuGc) by CMP-sialic acid hydroxylase. NeuGc is not produced by human and therefore immunogenic, antisense knockdown of CMP-sialic acid hydroxylase has been engineered in CHO to reduce NeuGc down to 1% [61].

O-linked glycan such as sialyl Lewis X (sLe\(^x\)) in E-Selectin protein is important for mediating cell adhesion. This glycan formation can be promoted by overexpressing \(\beta\)1,6-N-acetyl-glucosaminyltransferase (C2GnT) and fucosyltransferase 6 (Fut6), as well as downregulating ST3Gal [62, 63].

Another well-known direction of cell line engineering in glycosylation is modulating antibody effector function [144, 204]. N-glycans in the Fc-region play a critical role in ADCC activity. Absence of a core \(\alpha\)-1, 6-linked fucose improves binding to Fc\(\gamma\)RIII and the \textit{in vitro} ADCC activity [205, 206]. Defucosylated anti-CCR4 antibody mogamulizumab (KW0761) has been approved in Japan for relapsed adult T-cell leukemia-lymphoma [123]. Knockingdown \(\alpha\)-1,6-fucosyltransferase (Fut8) [65] and GDP-mannose 4,6-dehydrogenase (GMD) with siRNAs [64], homologous recombinant fut8 knockout [67], zinc-finger nucleases fut8 knockout [207], or overexpressing N-acetyl-glucosaminyltransferase III (GnTIII) [66] have been utilized for modifying fucosylation of IgG Fc glycans. Glycoengineered anti-CD20 antibody obinutuzumab (GA101) is currently used in clinical studies [208]. Inactivating GnTI in CHO cells (LecI) also generates a fucose-free oligomannose
glycan with enhanced ADCC and decreased complement-dependent cytotoxicity (CDC) activities for IgG [69]. Oligomannose glycan generated by the Lec1 mutant has been employed for targeted delivery to disease-affected tissues for the treatment of lysosomal storage diseases [68].

Besides glycosylation, cell line engineering has been applied for improving carboxylation modification. In order to improve carboxylation rate of factor X, a HEK293 line with overexpressing vitamin K epoxide reductase is constructed [71]. It has been shown that factor X in such a cell line is 92% carboxylated, up from control 52%. Interestingly, overexpressing the GGCGX, the carboxylase, has no improvement for the modification. It is presumably due to the fact that the reduction of vitamin K epoxide to vitamin K and the conversion of vitamin K to vitamin K hydroquinone are the rate-limiting steps under the culture condition. Similarly, overexpressing VKOR in HEK293 cells together with shRNA knockdown of calumenin (an inhibitor of VKOR and γ-carboxylase) increases the fraction of bioactive factor VII by sevenfold [72]. Recombinant factor IX is produced by a CHO line engineered to coexpress Furin protein [209]. This modification enhances propeptide removal and consequentially the factor IX activity, as failure to remove propeptide prevents the GlA domain from adopting proper calcium-induced conformation.

6.3. Applications in Process Engineering. A number of bioprocessing parameters can influence protein modification such as glycosylation [210]. They include serum content, culture pH, dissolved oxygen, temperature, growth phase, ammonium concentration, and salt concentration [75, 210–218]. Glycan degradation mediated by exoglycosidases such as sialidase and galactosidase also affects product consistency through cell viability and growth condition [202, 219]. Site occupancy for N- and O-linked glycosylation varies according to culture condition. These effects on modification have been attributed to availability of dolichol phosphate and nucleotide sugars [220], glycosyltransferase activity [221, 222], and potential modification site competing with protein folding [223, 224]. Ammonium is a common metabolic waste product driven by a major energy source of glutamine or asparagines. Increased ammonia levels in the cell culture can increase the pH of trans-Golgi compartment, therefore compromise pH-sensitive glycosyltransferases activity [215, 225].

Several strategies in process engineering have been developed to improve product quality and attributes. Glucosamine and uridine supplementation into CHO cell culture has led to an elevated level of intracellular UDP-GlcNAc and enhanced glycan antennarity [73]. Addition of CMP-Neu5Ac precursor, N-acetylmannosamine (ManNAc), can improve sialylation of IFN-gamma [76]. Feeding specific lipid supplements to cultures has been found to reduce the deterioration in site occupancy of IFN-gamma during batch culture [74]. OST enzyme requires manganese for maximal activity, therefore supplement with additional manganese or iron can increase glycan site occupancy of human tissue plasminogen activator [75]. Manganese addition to the production process of human EPO can also increase galactosylation and reduce lower sialylated fraction [226]. Decreasing culture temperature from 37°C to 33°C or 31°C, and adding butyrate or thyroid hormones, can increase glycan occupancy rate. Both butyrate addition and lowering temperatures decrease cell growth and therefore slow down the protein elongation rate which increases the exposure time of glycan site to OST enzyme in ER. Trace amount of metals affects glycosylation. Addition of copper (II) chloride is found to increase sialic acid content [218, 227]. To generate nonfucosylated oligomannose modified antibody, Zhou et al. added a potent α-mannosidase I inhibitor, kifunensine, to CHO cells for 11 days in batch culture [77]. The resulting antibody shows a greater affinity to FcyRIIIA, a higher ADCC activity, a lower binding to C1q, and a lower CDC activity. Glycation is a source of heterogeneity for recombinant therapeutic proteins. Yuk and coworkers demonstrate that by lowering the concentration of glucose from 6 g/L down to 3 g/L, >40% reduction in glycation is observed [78]. A >80% reduction is further generated with a fully continuous glucose fed at ~1 g/L.

7. Conclusions and Perspectives

The importance of protein modifications and their underlying mechanisms has become a core and focus of both industrial and basic research investigations. They can potentially affect protein production level, stability, pharmacokinetics/pharmacodynamics parameters, and immunogenicity. The functional and safety consequences of any of these modifications to a therapeutic protein must be evaluated on an individual protein basis. Advances in understanding the relationship between modification structure and function have enabled the rational designs to enhance specific functional features as demonstrated by the studies previously mentioned. Also this knowledge contributes to imposing strategic bioprocessing controls to ensure consistency of product quality. While glycosylation represents the most widespread and complex modification, other protein modifications such as phosphorylation and sulfation attract increasing attentions in recent years. Knowledge gaps remain for the understanding of the biology of these modifications. A recent report on the draft genome sequence of an ancestral CHO line [228] opens a new door for feasibility manipulating gene products involved in protein modification pathways. A further fundamental understanding of therapeutic protein modifications will culminate in the development of many new generations of biopharmaceutical products with preselected modifications and enhanced properties.

Acknowledgments

The authors would like to thank Ronald Kriz and Will Somers for critical reading of the paper. They would also like to apologize to all research groups whose work could not be included due to space and scope limitations.
References

[1] O. Hammarsten, “Zur Frage, ob das Casein ein einheitlicher Stoff sei;” Zeitschrift für Physiologische Chemie, vol. 7, pp. 227–273, 1883.

[2] V. S. Tagliabracci, J. L. Engel, J. Wen et al., “Secreted kinase phosphorylates extracellular proteins that regulate biomineralization,” Science, vol. 336, pp. 1150–1153, 2012.

[3] S. Kornfeld, “Foreword from first edition,” in Essentials of Glycobiology, A. Varki, R. D. Cummings, J. D. Esko et al., Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2nd edition, 2009.

[4] R. G. Krishna and F. Wold, “Post-translational modification of proteins,” Advances in Enzymology and Related Areas of Molecular Biology, vol. 67, pp. 265–298, 1993.

[5] J. Seo and K. J. Lee, “Post-translational modifications and their biological functions: proteomic analysis and systematic approaches,” Journal of Biochemistry and Molecular Biology, vol. 37, no. 1, pp. 35–44, 2004.

[6] B. Higgins, Post Translational Processing: A Practical Approach, Oxford University Press, 1999.

[7] C. Kannicht, Post Translational Modification of Proteins, Humana Press, 2002.

[8] N. Jenkins, “Modifications of therapeutic proteins: challenges and prospects,” Cytotechnology, vol. 53, no. 1–3, pp. 121–125, 2007.

[9] G. Walsh, “Post-translational modifications of protein biopharmaceuticals,” Drug Discovery Today, vol. 15, no. 17-18, pp. 773–780, 2010.

[10] G. Walsh and R. Jefferis, “Post-translational modifications in the context of therapeutic proteins,” Nature Biotechnology, vol. 24, no. 10, pp. 1241–1252, 2006.

[11] B. A. Gibson and W. L. Kraus, “New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs,” Nature Reviews Molecular Cell Biology, vol. 13, pp. 411–424, 2012.

[12] M. Mann and O. N. Jensen, “Proteomic analysis of post-translational modifications,” Nature Biotechnology, vol. 21, no. 3, pp. 255–261, 2003.

[13] J. P. Perry, J. A. Tainer, and M. N. Boddy, “A SIM-ultaneous role for SUMO and ubiquitin,” Trends in Biochemical Sciences, vol. 33, no. 5, pp. 201–208, 2008.

[14] D. Vucic, V. M. Dixit, and I. E. Wertz, “Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death,” Nature Reviews Molecular Cell Biology, vol. 12, no. 7, pp. 439–452, 2011.

[15] H. Liu, G. Caza-Bulsce, D. Faldu, C. Chumsae, and J. Sun, “Heterogeneity of monoclonal antibodies,” Journal of Pharmaceutical Sciences, vol. 97, no. 7, pp. 2426–2427, 2008.

[16] A. S. De Groot, “Immunomics: discovering new targets for vaccines and therapeutics,” Drug Discovery Today, vol. 11, no. 5-6, pp. 203–209, 2006.

[17] T. Schwartz and G. Blobel, “Structural basis for the function of the β subunit of the eukaryotic signal recognition particle receptor,” Cell, vol. 112, no. 6, pp. 793–803, 2003.

[18] A. R. Osborne, T. A. Rapoport, and B. Van Den Berg, “Protein translocation by the Sec61/SecY channel,” Annual Review of Cell and Developmental Biology, vol. 21, pp. 529–550, 2005.

[19] C. Hwang, A. J. Sinskey, and H. E. Lodish, “Oxidized redox state of glutathione in the endoplasmic reticulum,” Science, vol. 257, no. 5076, pp. 1496–1502, 1992.

[20] A. Fassio and R. Sita, “Formation, isomerisation and reduction of disulphide bonds during protein quality control in the endoplasmic reticulum,” Histochemistry and Cell Biology, vol. 117, no. 2, pp. 151–157, 2002.

[21] C. S. Sevier and C. A. Kaiser, “Conservation and diversity of the cellular disulfide bond formation pathways,” Antioxidants and Redox Signaling, vol. 8, no. 5-6, pp. 797–811, 2006.

[22] T. Schwartz and R. Sita, “Oxidative protein folding in the secretory pathway and redox signaling across compartments and cells,” Traffic, vol. 12, no. 1, pp. 1–8, 2011.

[23] A. R. Frand, J. W. Cuzzo, and C. A. Kaiser, “Pathways for protein disulfide bond formation,” Trends in Cell Biology, vol. 10, no. 5, pp. 203–210, 2000.

[24] C. S. Sevier, “New insights into oxidative folding,” Journal of Cell Biology, vol. 188, no. 6, pp. 757–758, 2010.

[25] W. Zhang and M. J. Czupryn, “Free sulfhydryl in recombinant monoclonal antibodies,” Biotechnology Progress, vol. 18, no. 3, pp. 509–513, 2002.

[26] H. Liu and K. May, “Disulphide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function,” mAbs, vol. 4, pp. 17–23, 2012.

[27] Y. D. Liu, T. Wang, R. Chou et al., “IgG2 disulfide isofrom conversion kinetics,” Molecular Immunology, vol. 54, pp. 217–226, 2013.

[28] S. Gu, D. Wen, P. H. Weinreb et al., “Characterization of trisulfide modification in antibodies,” Analytical Biochemistry, vol. 400, no. 1, pp. 89–98, 2010.

[29] G. L. Nelsestuen, T. H. Zytkovicz, and J. B. Howard, “The mode of action of vitamin K. Identification of γ carboxyglutamyl acid as a component of prothrombin,” The Journal of Biological Chemistry, vol. 249, no. 19, pp. 6347–6350, 1974.

[30] J. Stenflo, P. Fernlund, W. Egan, and P. Roepstorff, “Vitamin K dependent modifications of glutamic acid residues in prothrombin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 7, pp. 2730–2733, 1974.

[31] B. Furie and B. C. Furie, “Molecular basis of vitamin K-dependent γ-carboxylation,” Blood, vol. 75, no. 9, pp. 1753–1762, 1990.

[32] S. M. Wu, W. Cheung, F. D. Frazier, and D. W. Stafford, “Cloning and expression of the cDNA for human γ-glutamyl carboxylase,” Science, vol. 254, no. 5038, pp. 1634–1636, 1991.

[33] T. Li, C. Y. Chang, D. Y. Jin, P. J. Lin, A. Khvorova, and D. W. Stafford, “Identification of the gene for vitamin K epoxide reductase,” Nature, vol. 427, no. 6974, pp. 541–544, 2004.

[34] P. K. Bandyopadhyay, “Vitamin K-dependent γ-glutamylcarboxylation: an ancient posttranslational modification,” Vitamins and Hormones, vol. 78, pp. 157–184, 2008.

[35] L. M. Brown, “Biopharmaceuticals: post-translational modification carboxylation and hydroxylation,” in Post-Translational Modification of Protein Biopharmaceuticals, G. Walsh, Ed., Wiley-VCH, Weinheim, Germany, 2009.

[36] R. J. Kaufman, “Post-translational modifications required for coagulation factor secretion and function,” Thrombosis and Haemostasis, vol. 79, no. 6, pp. 1068–1079, 1998.

[37] R. M. Camire, P. J. Larson, D. W. Stafford, and K. A. High, “Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide,” Biochemistry, vol. 39, no. 46, pp. 14322–14329, 2000.

[38] L. Thin, S. Bjorn, M. Christensen et al., “Amino acid sequence and posttranslational modifications of human factor VIIa from
plasma and transfected baby hamster kidney cells," Biochemistry, vol. 27, no. 20, pp. 7785–7793, 1988.

[39] S. C. B. Yan, P. Razzano, Y. B. Chao et al., "Characterization and novel purification of recombinant human protein C from three mammalian cell lines," Bio/Technology, vol. 8, no. 7, pp. 655–661, 1990.

[40] T. Drakenberg, P. Fernlund, P. Roepstorff, and J. Stenflo, "\(\beta\)-hydroxyasparagine in vitamin K-dependent protein C," Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 7, pp. 1802–1806, 1983.

[41] R. S. Gronke, W. J. VanDusen, V. M. Garsky et al., "Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 10, pp. 3609–3613, 1989.

[42] S. Jia, W. J. VanDusen, R. E. Diehl et al., "cDNA cloning and expression of bovine aspartyl (asparaginyl) \(\beta\)-hydroxylase," The Journal of Biological Chemistry, vol. 267, no. 20, pp. 14322–14327, 1992.

[43] J. Stenflo, E. Holme, S. Lindstedt et al., "Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 2, pp. 444–447, 1989.

[44] J. Stenflo, A. Lundwall, and B. Dahlback, "\(\beta\)-hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S," Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 2, pp. 368–372, 1989.

[45] C. K. Derian, W. VanDusen, G. T. Przysiecki et al., "Inhibitors of 2-ketoglutarate-dependent dioxygenases block aspartyl beta-hydroxylation of recombinant human factor IX in several mammalian expression systems," The Journal of Biological Chemistry, vol. 264, no. 12, pp. 6615–6618, 1989.

[46] A. J. Gale and J. L. Pellequer, "An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa," Journal of Thrombosis and Haemostasis, vol. 1, no. 9, pp. 1966–1971, 2003.

[47] Y. Reiter, U. Brinkmann, B. Lee, and I. Pastan, "Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments," Nature Biotechnology, vol. 14, no. 10, pp. 1239–1245, 1996.

[48] S. Elliott, T. Lorenzini, S. Asher et al., "Enhancement of therapeutic protein in vivo activities through glycoengineering," Nature Biotechnology, vol. 21, no. 4, pp. 414–421, 2003.

[49] R. B. Pepinsky, L. Silvian, S. A. Berkowitz et al., "Improving the solubility of anti-LINGO-1 monoclonal antibody L133 by isotype switching and targeted mutagenesis," Protein Science, vol. 19, no. 5, pp. 954–966, 2010.

[50] S. J. Wu, J. Luo, K. T. O’Neil et al., "Structure-based engineering of a monoclonal antibody for improved solubility," Protein Engineering, Design and Selection, vol. 23, no. 8, pp. 643–651, 2010.

[51] F. Fares, A. Havron, and E. Fima, "Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin \(\beta\) subunit to the N-terminal and C-terminal coding sequence," International Journal of Cell Biology, vol. 2011, Article ID 275063, 7 pages, 2011.

[52] F. A. Fares, N. Suganuma, K. Nishimori, P. S. LaPolt, A. J. W. Hsueh, and I. Boime, "Design of a long-acting follitropin \(\beta\) agonist by fusing the C-terminal sequence of the chorionic gonadotropin \(\beta\) subunit to the follitropin \(\beta\) subunit," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4304–4308, 1992.

[53] X. Zhong, E. Kieras, E. Sousa et al., "Pyrogulutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions," The Journal of Biological Chemistry, vol. 288, no. 2, pp. 1409–1419, 2013.

[54] S. W. Pipe and R. J. Kaufman, "Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 22, pp. 11851–11856, 1997.

[55] Y. T. Jeong, O. Choi, Y. D. Son, S. Y. Park, and J. H. Kim, "Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cells," Biotechnology and Applied Biochemistry, vol. 52, no. 4, pp. 283–291, 2009.

[56] N. S. C. Wong, M. G. S. Yap, and D. I. C. Wang, "Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells," Biotechnology and Bioengineering, vol. 93, no. 5, pp. 1005–1016, 2006.

[57] K. Bork, W. Reutter, W. Weidemann, and R. Horstkorte, "Enhanced sialylation of EPO by overexpression of UDP-GlcNAc 2-epimerase/MannAc kinase containing a sialuria mutation in CHO cells," FEBS Letters, vol. 581, no. 22, pp. 4195–4198, 2007.

[58] Y. T. Jeong, O. Choi, H. R. Lim, Y. D. Son, H. J. Kim, and J. H. Kim, "Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expression," Journal of Microbiology and Biotechnology, vol. 18, no. 12, pp. 1945–1952, 2008.

[59] J. Ferrari, J. Gunson, J. Lofgren, L. Krummen, and T. G. Warner, "Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid," Biotechnology and Bioengineering, vol. 60, pp. 589–595, 1998.

[60] F. A. Ngantung, P. G. Miller, F. R. Brushett, G. L. Tang, and D. I. C. Wang, "RNA interference of sialidase improves glycoprotein sialic acid content consistency," Biotechnology and Bioengineering, vol. 95, no. 1, pp. 106–119, 2006.

[61] S. Chenu, A. Grégoire, Y. Malych et al., "Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy," Biochimica et Biophysica Acta, vol. 1622, no. 2, pp. 133–144, 2003.

[62] E. G. Prati, M. Matasci, T. B. Suter, A. Dinter, A. R. Sburlati, and J. E. Bailey, "Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-glycosylation pathway in Chinese hamster ovary (CHO) cells," Biotechnology and Bioengineering, vol. 68, pp. 239–244, 2000.

[63] E. G. Prati, P. Scheiddegger, A. R. Sburlati, and J. E. Bailey, "Antisense strategies for glycosylation engineering of Chinese hamster ovary (CHO) cells," Biotechnology and Bioengineering, vol. 59, pp. 445–450, 1998.

[64] H. Imai-Nishiya, K. Mori, M. Inoue et al., "Double knockdown of \(\alpha\)-6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC," BMC Biotechnology, vol. 7, article 84, 2007.
[65] K. Mori, R. Kuni-Kamochi, N. Yamane-Ohnuki et al., “Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA,” *Biotechnology and Bioengineering*, vol. 88, no. 7, pp. 901–908, 2004.

[66] C. Ferrara, P. Brünker, T. Suter, S. Moser, U. Püntener, and P. Umana, “Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II,” *Biotechnology and Bioengineering*, vol. 93, no. 5, pp. 851–861, 2006.

[67] N. Yamane-Ohnuki, S. Kinoshita, M. Inoue-Urakubo et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity,” *Biotechnology and Bioengineering*, vol. 87, no. 5, pp. 614–622, 2004.

[68] S. M. Van Patten, H. Hughes, M. R. Huff et al., “Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease,” *Glycobiology*, vol. 17, no. 5, pp. 467–478, 2007.

[69] X. Zhong, C. Cooley, N. Seth et al., “Engineering novel Lecl glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I,” *Biotechnology and Bioengineering*, vol. 109, pp. 1723–1734, 2012.

[70] M. F. Naso, S. H. Tam, B. J. Scallon, and T. S. Raju, “Engineering host cell lines to reduce terminal sialylation of secreted antibodies,” *mAbs*, vol. 2, no. 5, pp. 519–527, 2010.

[71] Y. M. Sun, D. Y. Jin, R. M. Camire, and D. W. Stafford, “Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X,” *Blood*, vol. 106, no. 12, pp. 3811–3815, 2005.

[72] N. Wajih, J. Owen, and R. Wallin, “Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKO/KOI where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection,” *Thrombosis Research*, vol. 122, no. 3, pp. 405–410, 2008.

[73] K. N. Baker, M. H. Rendall, A. E. Hills, M. Hoare, R. B. Freedman, and D. C. James, “Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells,” *Biotechnology and Bioengineering*, vol. 73, no. 3, pp. 188–202, 2001.

[74] N. Jenkins, P. Castro, S. Menon, A. Ison, and A. Bull, “Effect of lipid supplements on the production and glycosylation of recombinant interferon-γ expressed in CHO cells,” *Cytotechnology*, vol. 15, no. 1–3, pp. 209–215, 1994.

[75] M. Gawlitze, M. Estacio, T. Führ, and R. Kiss, “Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells,” *Biotechnology and Bioengineering*, vol. 103, no. 6, pp. 1164–1175, 2009.

[76] X. Gu and D. I. Wang, “Improvement of interferon-gamma sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine,” *Biotechnology and Bioengineering*, vol. 58, pp. 642–648, 1998.

[77] Q. Zhou, S. Shankara, A. Roy et al., “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,” *Biotechnology and Bioengineering*, vol. 99, no. 3, pp. 652–665, 2008.

[78] I. H. Yuk, B. Zhang, Y. Yang et al., “Controlling glycation of recombinant antibody in fed-batch cell cultures,” *Biotechnology and Bioengineering*, vol. 108, pp. 2600–2610, 2011.

[79] S. Emr, B. S. Glick, A. D. Linsteadt et al., “Journeys through the Golgi—taking stock in a new era,” *Journal of Cell Biology*, vol. 187, no. 4, pp. 449–453, 2009.

[80] C. Wilson, R. Venditti, L. R. Rega, A. Colanzi, G. D’Angelo, and M. A. De, “The Golgi apparatus: an organelle with multiple complex functions,” *Biochemical Journal*, vol. 433, no. 1, pp. 1–9, 2011.

[81] W. B. Huttner, “Tyrosine sulfation and the secretory pathway,” *Annual Review of Physiology*, vol. 50, pp. 363–376, 1988.

[82] F. R. Bettelheim, “Tyrosine-O-sulfate in a peptide from fibrinogen,” *Journal of the American Chemical Society*, vol. 76, no. 10, pp. 2838–2839, 1954.

[83] J. W. Kehoe and C. R. Bertozzi, “Tyrosine sulfation: a modulator of extracellular protein–protein interactions,” *Chemistry and Biology*, vol. 7, no. 3, pp. R57–R61, 2000.

[84] K. L. Moore, “The biology and enzymology of protein tyrosine O-sulfation,” *The Journal of Biological Chemistry*, vol. 278, no. 27, pp. 24243–24246, 2003.

[85] C. Seibert and T. P. Sakmar, “Toward a framework for sulfoproteomics: synthesis and characterization of sulfotyrosine-containing peptides,” *Biopolymers*, vol. 90, no. 3, pp. 459–477, 2008.

[86] M. J. Stone, S. Chuang, X. Hou, M. Shoham, and J. Z. Zhu, “Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins,” *New Biotechnology*, vol. 25, no. 5, pp. 299–317, 2009.

[87] R. Beisswanger, D. Corbel, C. Vannier et al., “Existence of distinct tyrosylprotein sulfotransferase genes: molecular characterization of tyrosylprotein sulfotransferase-2,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 19, pp. 11134–11139, 1998.

[88] Y. B. Ouyang, W. S. Lane, and K. L. Moore, “Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 6, pp. 2896–2901, 1998.

[89] Y. B. Ouyang and K. L. Moore, “Molecular cloning and expression of human and mouse tyrosylprotein sulfotransferase-2 and a tyrosylprotein sulfotransferase homologue in Caenorhabditis elegans,” *The Journal of Biological Chemistry*, vol. 273, no. 38, pp. 24770–24774, 1998.

[90] P. A. Baueerle and W. B. Huttner, “Tyrosine sulfation is a trans-Golgi-specific protein modification,” *Journal of Cell Biology*, vol. 105, no. 6, pp. 2655–2664, 1987.

[91] R. W. H. Lee and W. B. Huttner, “(Glu62, Ala30, Tyr8)n serves as a tyrosylprotein sulfotransferase homologue in Caenorhabditis elegans,” *The Journal of Biological Chemistry*, vol. 265, no. 19, pp. 11134–11139, 2009.

[92] C. Niehrs, M. Kraft, R. W. H. Lee, and W. B. Huttner, “Analysis of the substrate specificity of tyrosylprotein sulfotransferase using synthetic peptides,” *The Journal of Biological Chemistry*, vol. 265, no. 15, pp. 8525–8532, 1990.

[93] C. Niehrs, W. B. Huttner, D. Carvallo, and E. Degryse, “Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferases,” *The Journal of Biological Chemistry*, vol. 265, no. 16, pp. 9314–9318, 1990.

[94] T. J. Rydel, K. G. Ravichandran, A. Tulinsky et al., “The structure of a complex of recombinant hirudin and human α-thrombin,” *Science*, vol. 249, no. 4966, pp. 277–280, 1990.
[127] H. P. J. Bennett, C. A. Browne, and S. Solomon, “Biosynthesis of phosphorylated forms of corticotropin-related peptides,” *Procedures of the National Academy of Sciences of the United States of America*, vol. 78, no. 8, pp. 4713–4717, 1981.

[128] G. J. Dockray, A. Varro, H. Desmond, J. Young, H. Gregory, and R. A. Gregory, “Post-translational processing of the porcine gastrin precursor by phosphorylation of the COOH-terminal fragment,” *The Journal of Biological Chemistry*, vol. 262, no. 18, pp. 8643–8647, 1987.

[129] A. F. Bradbury and D. G. Smyth, “Peptide amidation,” *Trends in Biochemical Sciences*, vol. 16, no. 3, pp. 112–115, 1991.

[130] S. T. Prigge, R. E. Mains, B. A. Eipper, and L. M. Amzel, “New insights into copper monooxygenases and peptide amidation: structure, mechanism and function,” *Cellular and Molecular Life Sciences*, vol. 57, no. 8-9, pp. 1236–1259, 2000.

[131] S. L. Milgram, B. A. Eipper, and R. E. Mains, “Differential trafficking of soluble and integral membrane secretary granule-associated proteins,” *Journal of Cell Biology*, vol. 124, no. 1-2, pp. 33–41, 1994.

[132] M. V. L. Ray, P. Van Duyne, A. H. Bertelsen et al., “Production of recombinant salmon calcitonin by in vitro amidation of an Escherichia coli produced precursor peptide,” *Bio/Technology*, vol. 11, no. 1, pp. 64–70, 1993.

[133] I. Takahashi, Y. C. Liu, N. Hayashi et al., “Production of bioactive salmon calcitonin from the nonendocrine cell lines COS-7 and CHO,” *Peptides*, vol. 18, no. 3, pp. 439–444, 1997.

[134] B. S. Wulff, B. Catiopicov, H. Okamoto, U. Gether, T. W. Schwartz, and T. E. Johansen, “Efficient amidation of C-peptide deleted NPY precursors by non-endocrine cells is affected by the presence of Lys-Arg at the C-termius,” *Molecular and Cellular Endocrinology*, vol. 91, no. 1-2, pp. 135–141, 1993.

[135] K. W. Moremen, M. Tiemeyer, and A. V. Nairn, “Vertebrate protein glycosylation: diversity, synthesis and function,” *Nature Reviews Molecular Cell Biology*, vol. 13, pp. 448–462, 2012.

[136] A. Helenius and M. Aebi, “Roles of N-linked glycans in the endoplasmic reticulum,” *Annual Review of Biochemistry*, vol. 73, pp. 1019–1049, 2004.

[137] R. Kornfeld and S. Kornfeld, “Assembly of asparagine-linked oligosaccharides,” *Annual Review of Biochemistry*, vol. 54, pp. 631–664, 1985.

[138] J. Stenflo and P. Fernlund, “Amino acid sequence of the heavy chain of bovine protein C,” *The Journal of Biological Chemistry*, vol. 257, no. 20, pp. 12180–12190, 1982.

[139] E. Bause and G. Legler, “The role of the hydroxy amino acid in the triplet sequence Asn-Xaa-Thr(Ser) for the N-glycosylation step during glycoprotein biosynthesis,” *Biochemical Journal*, vol. 195, no. 3, pp. 639–644, 1981.

[140] J. F. Valier盟-Douglass, C. M. Eakin, A. Wallace et al., “Glutamine-linked and non-consensus asparagine-linked oligosaccharides present in human recombinant antibodies define novel protein glycosylation motifs,” *The Journal of Biological Chemistry*, vol. 285, no. 21, pp. 16012–16022, 2010.

[141] P. Stanley, H. Schachter, and N. Taniguchi, “N-glycans,” in *Essentials of Glycobiology*, A. Varki, R. D. Cummings, J. D. Esko et al., Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2009.

[142] C. B. Hirschberg and M. D. Snider, “Topography of glycosylation in the rough endoplasmic reticulum and Golgi apparatus,” *Annual Review of Biochemistry*, vol. 56, pp. 63–87, 1987.

[143] D. J. Kelleher and R. Gilmore, “An evolving view of the eukaryotic oligosaccharyltransferase,” *Glycobiology*, vol. 16, no. 4, pp. 47R–62R, 2006.

[144] R. Jefferis, “Glycosylation as a strategy to improve antibody-based therapeutics,” *Nature Reviews Drug Discovery*, vol. 8, no. 3, pp. 226–234, 2009.

[145] J. Qian, T. Liu, L. Yang, A. Daus, R. Crowley, and Q. Zhou, “Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion,” *Analytical Biochemistry*, vol. 364, no. 1, pp. 8–18, 2007.

[146] J. Egrie, J. Grant, D. Gillies, K. Aoki, and T. Strickland, “The role of carbohydrate on the biological activity of erythropoietin,” *Glycocomjugate Journal*, vol. 10, pp. 263, 1993.

[147] S. Pestka, J. A. Langer, K. C. Zoon, and C. E. Samuel, “Interferons and their actions,” *Annual Review of Biochemistry*, vol. 56, pp. 727–777, 1987.

[148] A. Ulloa-Aguirre, C. Timossi, P. Damián-Matsumura, and J. A. Dias, “Role of glycosylation in function of follicle-stimulating hormone,” *Endocrine*, vol. 12, no. 3, pp. 205–215, 1999.

[149] Y. Vugmeyer, X. Xu, F. P. Theil, L. A. Khawli, and M. W. Leach, “Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges,” *World Journal of Biological Chemistry*, vol. 3, pp. 73–92, 2012.

[150] M. Manning, K. Patel, and R. T. Borchardt, “Stability of protein pharmaceuticals,” *Pharmaceutical Research*, vol. 6, no. 11, pp. 903–918, 1989.

[151] H. T. Wright, “Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins,” *Critical Reviews in Biochemistry and Molecular Biology*, vol. 26, no. 1, pp. 1–52, 1991.

[152] T. Geiger and S. Clarke, “Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation,” *The Journal of Biological Chemistry*, vol. 262, no. 2, pp. 785–794, 1987.

[153] C. I. Neglia, H. J. Cohen, A. R. Garber, P. D. Ellis, S. R. Thorpe, and J. W. Baynes, “13C NMR investigation of nonenzymatic glucosylation of protein. Model studies using RNase A,” *The Journal of Biological Chemistry*, vol. 258, no. 23, pp. 14279–14283, 1983.

[154] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

[155] H. V. Miranda and T. F. Outeiro, “The sour side of neurodegenerative disorders: the effects of protein glycation,” *Journal of Pathology*, vol. 221, no. 1, pp. 13–25, 2010.

[156] L. J. Brady, T. Martinez, and A. Balland, “Characterization of nonenzymatic glycation on a monoclonal antibody,” *Analytical Chemistry*, vol. 79, no. 2, pp. 179–191, 2008.

[157] C. Quan, E. Alcala, I. Petkovska et al., “A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior,” *Analytical Biochemistry*, vol. 373, no. 2, pp. 179–191, 2008.

[158] S. Fischer, J. Hoernschemeyer, and H. C. Mahler, “Glycation during storage and administration of monoclonal antibody formulations,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 70, no. 1, pp. 42–50, 2008.

[159] J. D. Andya, Y. F. Maa, H. R. Costantino et al., “The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody,” *Pharmaceutical Research*, vol. 16, no. 3, pp. 350–358, 1999.
carboxyl-terminal peptide of human chorionic gonadotropin \(\beta\)-subunit to the coding sequence of hGH," Endocrinology, vol. 151, no. 9, pp. 4410–4417, 2010.

[194] D. T. Berg, B. Gerlitz, J. Shang et al., "Engineering the proteolytic specificity of activated protein C improves its pharmacological properties," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4423–4428, 2003.

[195] E. Grubenhorst, P. Schlenke, S. Pohl, M. Nimtz, and H. S. Conradt, "Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells," Glycoconjugate Journal, vol. 16, no. 2, pp. 81–97, 1999.

[196] Y. Lim, N. S. C. Wong, Y. Y. Lee, S. C. Y. Ku, D. C. F. Wong, and M. G. S. Yap, "Engineering mammalian cells in bioprocessing—current achievements and future perspectives," Biotechnology and Applied Biochemistry, vol. 55, no. 4, pp. 175–189, 2010.

[197] K. Fukuta, R. Abe, T. Yokomatsu et al., "Remodeling of sugar chain structures of human interferon-\(\gamma\)," Glycobiology, vol. 10, no. 4, pp. 421–430, 2000.

[198] K. Fukuta, T. Yokomatsu, R. Abe, M. Asanagi, and T. Makino, "Genetic engineering of CHO cells producing human interferon-\(\gamma\)-y by transfection of sialyltransferases," Glycoconjugate Journal, vol. 17, no. 12, pp. 895–904, 2000.

[199] A. Bragonzi, G. Distefano, L. D. Buckberry et al., "A new Chinese hamster ovary cell line expressing \(\alpha2,6\)-sialyltransferase used as universal host for the production of human sialylated recombinant glycoproteins," Biochimica et Biophysica Acta, vol. 1474, no. 3, pp. 273–282, 2000.

[200] T. Chitlaru, C. Kronman, M. Zeevi et al., "Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels," Biochemical Journal, vol. 336, no. 3, pp. 647–658, 1998.

[201] C. F. Goochee, M. J. Graemer, D. C. Andersen, J. B. Bahr, and J. R. Rasmussen, "The oligosaccharidases of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties," Bio/Technology, vol. 9, no. 12, pp. 1347–1355, 1991.

[202] M. J. Graemer and C. F. Goochee, "Glycosidase activities in Chinese hamster ovary cell lysate and cell culture supernatant," Biotechnology Progress, vol. 9, no. 4, pp. 366–373, 1993.

[203] M. J. Graemer, C. F. Goochee, V. Y. Chock, D. T. Broussseau, and M. B. Sliwkowski, "Removal of sialic acid from a glycoprotein in CHO cell culture supernatant by action of an extracellular CHO cell sialidase," Bio/Technology, vol. 13, no. 7, pp. 692–698, 1995.

[204] A. Natsume, K. Niwa, and M. Satoh, "Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC," Drug Design, Development and Therapy, vol. 3, pp. 7–16, 2009.

[205] A. Niwa, E. Shoji-Hosaka, M. Sakurada et al., "Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma," Cancer Research, vol. 64, no. 6, pp. 2127–2133, 2004.

[206] L. L. Shields, J. Lai, R. Keck et al., "Lack of fusoc on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity," The Journal of Biological Chemistry, vol. 277, no. 30, pp. 26733–26740, 2002.

[207] L. Malphettes, Y. Freyvert, J. Chang et al., "Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies," Biotechnology and Bioengineering, vol. 106, no. 5, pp. 774–783, 2010.

[208] L. H. Sihn, S. E. Assouline, D. A. Stewart et al., "A phase I study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies," Blood, vol. 119, pp. 5118–5125, 2012.

[209] M. Butler, "Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals," Applied Microbiology and Biotechnology, vol. 68, no. 3, pp. 283–291, 2005.

[210] W. S. Ahn, J. J. Jeon, Y. R. Jeong, J. L. Seung, and K. Y. Sung, "Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells," Biotechnology and Bioengineering, vol. 101, no. 6, pp. 1234–1244, 2008.

[211] D. C. Andersen, T. Bridges, M. Gawlitzek, and C. Hoy, "Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator," Biotechnology and Bioengineering, vol. 70, pp. 25–31, 2000.

[212] C. K. Crowell, Q. Qin, G. E. Grampp, R. A. Radcliffe, G. N. Rogers, and R. I. Scheinman, "Sodium butyrate alters erythropoietin glycosylation via multiple mechanisms," Biotechnology and Bioengineering, vol. 99, no. 1, pp. 201–213, 2008.

[213] D. A. Cumming, "Glycosylation of recombinant protein therapeutics: control and functional implications," Glycobiology, vol. 1, no. 2, pp. 115–130, 1991.

[214] M. Gawlitzek, T. Ryll, J. Lofgren, and M. B. Sliwkowski, "Amino acid alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms," Biotechnology and Bioengineering, vol. 68, pp. 637–646, 2000.

[215] C. F. Goochee, M. J. Graemer, D. C. Andersen, J. B. Bahr, and J. R. Rasmussen, "The oligosaccharidases of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties," Bio/Technology, vol. 9, no. 12, pp. 1347–1355, 1991.

[216] N. Jenkins, R. B. Parekh, and D. C. James, "Getting the glycosylation right: implications for the biotechnology industry," Nature Biotechnology, vol. 14, no. 8, pp. 975–981, 1996.

[217] E. Pacis, M. Yu, J. Autsen, R. Bayer, and F. Li, "Effects of cell culture conditions on antibody N-linked glycosylation—what affects high mannose 5 glycoform," Biotechnology and Bioengineering, vol. 108, no. 10, pp. 2348–2358, 2011.

[218] T. G. Warner, J. Chang, J. Ferrari et al., "Isolation and properties of a soluble sialidase from the culture fluid of Chinese hamster ovary cells," Glycobiology, vol. 3, no. 5, pp. 455–463, 1993.

[219] G. B. Nyberg, R. R. Balcarcel, B. D. Pollstad, G. Stephanopoulos, and D. I. Wang, "Metallic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells," Biotechnology and Bioengineering, vol. 62, pp. 336–347, 1999.

[220] T. L. Hendrickson and B. Imperiali, "Metal ion dependence of oligosaccharidase transferase: implications for catalysis," Biochemistry, vol. 34, no. 29, pp. 9444–9450, 1995.

[221] R. J. Kaufman, M. Svaroop, and P. Murtha-Ried, "Depletion of manganese within the secretory pathway inhibits O-linked glycosylation in mammalian cells," Biochemistry, vol. 33, no. 33, pp. 9813–9819, 1994.

[222] B. Holst, A. W. Bruun, M. C. Kielland-Brandt, and J. R. Winther, "Competition between folding and glycosylation in the endoplasmic reticulum," The EMBO Journal, vol. 15, no. 14, pp. 3538–3546, 1996.
[224] M. Shelikoff, A. J. Sinskey, and G. Stephanopoulos, “A modeling framework for the study of protein glycosylation,” *Biotechnology and Bioengineering*, vol. 50, pp. 73–90, 1996.

[225] M. Schneider, I. W. Marison, and U. Von Stockar, “The importance of ammonia in mammalian cell culture,” *Journal of Biotechnology*, vol. 46, no. 3, pp. 161–185, 1996.

[226] C. K. Crowell, G. E. Grampp, G. N. Rogers, J. Miller, and R. I. Scheinman, “Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system,” *Biotechnology and Bioengineering*, vol. 96, no. 3, pp. 538–549, 2007.

[227] L. Santell, T. Ryll, T. Etcheverry et al., “Aberrant metabolic sialylation of recombinant proteins expressed in Chinese hamster ovary cells in high productivity cultures,” *Biochemical and Biophysical Research Communications*, vol. 258, no. 1, pp. 132–137, 1999.

[228] X. Xu, H. Nagarajan, N. E. Lewis et al., “The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line,” *Nature Biotechnology*, vol. 29, no. 8, pp. 735–741, 2011.